You are here

References

1. Cause-Specific Mortality, 2008: WHO region. World Health Organization; 2012. (Accessed February 1, 2013, at http://apps.who.int/gho/data/#.)

2. IARC World Cancer Report 2008. International Agency for Research on Cancer; 2012. (Accessed February 7, 2013, at http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php.)

3. Summary of changes in cancer mortality, 1950-2007. National Cancer Institute; 2012. (Accessed February 7, 2013, at http://seer.cancer.gov/csr/1975_2007/results_merged/topic_historical_mort_trends.pdf.)

4. SEER Stat Fact Sheets: Stomach. National Cancer Institute; 2012. (Accessed March 11, 2013, at http://seer.cancer.gov/statfacts/html/stomach.html.)

5. Siegel R, Naishadham D, Jemal ACancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.

6. Estimated new cancer cases and deaths for 2012. National Cancer Institute; 2012. (Accessed February 7, 2013, at http://www.seer.cancer.gov/csr/1975_2009_pops09/results_single/sect_01_table.01.pdf.)

7. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917.

8. Munoz N, Correa P, Cuello C, Duque E. Histologic types of gastric carcinoma in high- and low-risk areas. Int J Cancer 1968; 3:809-18.

9. Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012; 21:36-51.

10. Fearon ER. Molecular genetics of colorectal cancer. Ann N Y Acad Sci 1995; 768:101-10.

11. McDonald SA, Greaves LC, Gutierrez-Gonzalez L, et al. Mechanisms of field cancerization in the human stomach: The expansion and spread of mutated gastric stem cells. Gastroenterology 2008; 134:500-10.

12. Munoz N, Matko I. Histological types of gastric cancer and its relationship with intestinal metaplasia. Recent Results Cancer Res 1972; 39:99-105.

13. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735-40.

14. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res 1990; 50:4737-40.

15. Cai X, Carlson J, Stoicov C, et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology 2005; 128:1937-52.

16. Lee CW, Rickman B, Rogers AB, et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 2008; 68:3540-8.

17. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012; 72:4383-93.

18. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19:257-72.

19. Jiang L, Gonda TA, Gamble MV, et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 2008; 68:9900-8.

20. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000; 29:559-78.

21. Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000; 54:615-40.

22. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134:306-23.

23. Ahmed A, Smoot D, Littleton G, et al. Helicobacter pylori inhibits gastric cell cycle progression. Microbes Infect 2000; 2:1159-69.

24. Suganuma M, Kurusu M, Okabe S, et al. Helicobacter pylori membrane protein 1: A new carcinogenic factor of Helicobacter pylori. Cancer Res 2001; 61:6356-9.

25. Baik SC, Youn HS, Chung MH, et al. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res 1996; 56:1279-82.

26. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345:784-9.

27. Hsu PI, Lai KH, Hsu PN, et al. Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 2007; 102:725-30.

28. Kamangar F, Qiao YL, Blaser MJ, et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 2007; 96:172-6.

29. Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006; 98:1445-52.

30. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100:1325-9.

31. Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118:2516-25.

32. Eaton KA, Mefford M, Thevenot T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 2001; 166:7456-61.

33. Roth KA, Kapadia SB, Martin SM, Lorenz RG. Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. J Immunol 1999; 163:1490-7.

34. Sutton P, Kolesnikow T, Danon S, et al. Dominant nonresponsiveness to Helicobacter pylori infection is associated with production of interleukin 10 but not gamma interferon. Infect Immun 2000; 68:4802-4.

35. Fox JG, Sheppard BJ, Dangler CA, et al. Germ-line p53 targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res 2002; 62:696-702.

36. Smythies LE, Waites KB, Lindsey JR, et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000; 165:1022-9.

37. Sawai N, Kita M, Kodama T, et al. Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 1999; 67:279-85.

38. Tu S, Quante M, Bhagat G, et al. Interferon-{gamma} inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T cell apoptosis. Cancer Res 2011; 71:4247-59.

39. Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118:1727-38.

40. Fox JG, Beck P, Dangler CA, et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat Med 2000; 6:536-42.

41. Segal I, Ally R, Mitchell H. Helicobacter pylori—An African perspective. QJM 2001; 94:561-5.

42. Whary MT, Sundina N, Bravo LE, et al. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: Possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev 2005; 14:1464-9.

43. Lee CW, Rickman B, Rogers AB, et al. Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 2009; 69:8166-74.

44. Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in H. pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011; 140:210-20.

45. Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001; 107:767-73.

46. Israel DA, Salama N, Krishna U, et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc Natl Acad Sci U S A 2001; 98:14625-30.

47. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388:539-47.

48. Kostrzynska M, Betts JD, Austin JW, Trust TJ. Identification, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella. J Bacteriol 1991; 173:937-46.

49. Kavermann H, Burns BP, Angermuller K, et al. Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med 2003; 197:813-22.

50. Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991; 338:332-5.

51. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: Importance of the cagA status. J Natl Cancer Inst 1995; 87:1777-80.

52. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55:2111-5.

53. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40:297-301.

54. Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A 2008; 105:1003-8.

55. Sharma SA, Tummuru MK, Miller GG, Blaser MJ. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun 1995; 63:1681-87.

56. Tummuru MK, Sharma SA, Blaser MJ. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol Microbiol 1995; 18:867-76.

57. Glocker E, Lange C, Covacci A, et al. Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kappaB activation. Infect Immun 1998; 66:2346-8.

58. Peek RM Jr, Miller GG, Tham KT, et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest 1995; 73:760-70.

59. Yamaoka Y, Kita M, Kodama T, et al. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996; 110:1744-52.

60. Ogura K, Maeda S, Nakao M, et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med 2000; 192:1601-10.

61. Israel DA, Salama N, Arnold CN, et al. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. J Clin Invest 2001; 107:611-20.

62. Gebert B, Fischer W, Weiss E, et al. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003; 301:1099-102.

63. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2:28-37.

64. Larsson SC, Bergkvist L, Wolk A. Processed meat consumption, dietary nitrosamines and stomach cancer risk in a cohort of Swedish women. Int J Cancer 2006; 119:915-9.

65. Knekt P, Jarvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: A follow-up study. Int J Cancer 1999; 80:852-6.

66. Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27:1497-501.

67. van Loon AJ, Botterweck AA, Goldbohm RA, et al. Intake of nitrate and nitrite and the risk of gastric cancer: A prospective cohort study. Br J Cancer 1998; 78:129-35.

68. Fox JG, Dangler CA, Taylor NS, et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999; 59:4823-8.

69. D’Elia L, Rossi G, Ippolito R, et al. Habitual salt intake and risk of gastric cancer: A meta-analysis of prospective studies. Clin Nutr 2012; 31:489-98.

70. Gonzalez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98:345-54.

71. Loh JT, Torres VJ, Cover TL. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res 2007; 67:4709-15.

72. Gamboa-Dominguez A, Ubbelohde T, Saqui-Salces M, et al. Salt and stress synergize H. pylori-induced gastric lesions, cell proliferation, and p21 expression in Mongolian gerbils. Dig Dis Sci 2007; 52:1517-26.

73. Kobayashi M, Tsubono Y, Sasazuki S, et al. Vegetables, fruit and risk of gastric cancer in Japan: A 10-year follow-up of the JPHC Study Cohort I. Int J Cancer 2002; 102:39-44.

74. Gonzalez CA, Lujan-Barroso L, Bueno-de-Mesquita HB, et al. Fruit and vegetable intake and the risk of gastric adenocarcinoma: A reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. Int J Cancer 2012; 131:2910-9.

75. Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15:1998-2001.

76. Freedman ND, Subar AF, Hollenbeck AR, et al. Fruit and vegetable intake and gastric cancer risk in a large United States prospective cohort study. Cancer Causes Control 2008; 19:459-67.

77. Tavani A, La Vecchia C, Gallus S, et al. Red meat intake and cancer risk: A study in Italy. Int J Cancer 2000; 86:425-8.

78. Ji BT, Chow WH, Yang G, et al. Dietary habits and stomach cancer in Shanghai, China. Int J Cancer 1998; 76:659-64.

79. Ward MH, Lopez-Carrillo L. Dietary factors and the risk of gastric cancer in Mexico City. Am J Epidemiol 1999; 149:925-32.

80. Ito LS, Inoue M, Tajima K, et al. Dietary factors and the risk of gastric cancer among Japanese women: A comparison between the differentiated and non-differentiated subtypes. Ann Epidemiol 2003; 13:24-31.

81. Botterweck AA, van den Brandt PA, Goldbohm RAVitamins, carotenoids, dietary fiber, and the risk of gastric carcinoma: Results from a prospective study after 6.3 years of follow-up. Cancer 2000; 88:737-48.

82. Ekstrom AM, Serafini M, Nyren O, et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: A population-based case-control study in Sweden. Int J Cancer 2000; 87:133-40.

83. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: Association by tumour type. J Intern Med 2002; 252:206-24.

84. Gonzalez CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107:629-34.

85. Sung NY, Choi KS, Park EC, et al. Smoking, alcohol and gastric cancer risk in Korean men: The National Health Insurance Corporation Study. Br J Cancer 2007; 97:700-4.

86. Sjodahl K, Lu Y, Nilsen TI, et al. Smoking and alcohol drinking in relation to risk of gastric cancer: A population-based, prospective cohort study. Int J Cancer 2007; 120:128-32.

87. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: Systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008; 19:689-701.

88. Zendehdel K, Nyren O, Luo J, et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008; 122:1095-9.

89. Stenstrom B, Zhao CM, Rogers AB, et al. Swedish moist snuff accelerates gastric cancer development in Helicobacter pylori-infected wild-type and gastrin transgenic mice. Carcinogenesis 2007; 28:2041-6.

90. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007; 165:1424-33.

91. Larsson SC, Giovannucci E, Wolk A. Alcoholic beverage consumption and gastric cancer risk: A prospective population-based study in women. Int J Cancer 2007; 120:373-7.

92. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89:1277-84.

93. Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2012; 23:28-36.

94. Duell EJ, Sala N, Travier N, et al. Genetic variation in alcohol dehydrogenase (ADH1A, ADH1B, ADH1C, ADH7) and aldehyde dehydrogenase (ALDH2), alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Carcinogenesis 2012; 33:361-7.

95. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-78.

96. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: A prospective cohort study. Gut 2007; 56:1503-11.

97. MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer 2006; 118:2628-31.

98. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90:150-5.

99. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005; 16:285-94.

100. O’Doherty MG, Freedman ND, Hollenbeck AR, et al. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut 2012; 61:1261-8.

101. Kant P, Hull MA. Excess body weight and obesity—The link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol 2011; 8:224-38.

102. Zanghieri G, Di Gregorio C, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 1990; 66:2047-51.

103. Brenner H, Arndt V, Sturmer T, et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000; 88:274-9.

104. Parsonnet J. When heredity is infectious. Gastroenterology 2000; 118:222-4.

105. Leung WK, Ng EK, Chan WY, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14:2982-6.

106. Yatsuya H, Toyoshima H, Tamakoshi A, et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: A nested case-control study. Br J Cancer 2004; 91:929-34.

107. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:78-85.

108. Chang YW, Han YS, Lee DK, et al. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. Int J Cancer 2002; 101:469-74.

109. El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: Critical role of H. pylori. Gastroenterology 2000; 118:22-30.

110. Stoicov C, Whary M, Rogers AB, et al. Coinfection modulates inflammatory responses and clinical outcome of Helicobacter felis and Toxoplasma gondii infections. J Immunol 2004; 173:3329-36.

111. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.

112. Figueiredo C, Machado JC, Pharoah P, et al. Helicobacter pylori and interleukin 1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94:1680-7.

113. Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123:92-105.

114. Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125:364-71.

115. Zeng ZR, Hu PJ, Hu S, et al. Association of interleukin 1β gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 2003; 52:1684-9.

116. Rad R, Prinz C, Neu B, et al. Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa. J Infect Dis 2003; 188:272-81.

117. Hwang IR, Hsu PI, Peterson LE, et al. Interleukin-6 genetic polymorphisms are not related to Helicobacter pylori-associated gastroduodenal diseases. Helicobacter 2003; 8:142-8.

118. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin 1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14:408-19.

119. El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124:1193-201.

120. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132:905-12.

121. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392:402-5.

122. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999; 8:607-10.

123. Shinmura K, Kohno T, Takahashi M, et al. Familial gastric cancer: Clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis 1999; 20:1127-31.

124. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297:2360-72.

125. Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: Diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 2008; 112:2655-63.

126. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121:1348-53.

127. Masciari S, Larsson N, Senz J, et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007; 44:726-31.

128. Schrader KA, Masciari S, Boyd N, et al. Hereditary diffuse gastric cancer: Association with lobular breast cancer. Fam Cancer 2008; 7:73-82.

129. Zwick A, Munir M, Ryan CK, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113:659-63.

130. Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:180-5.

131. Attard TM, Cuffari C, Tajouri T, et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004; 99:681-6.

132. Aarnio M, Salovaara R, Aaltonen LA, et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997; 74:551-5.

133. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998; 5:751-6.

134. Coburn MC, Pricolo VE, DeLuca FG, Bland KI. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2:386-91.

135. Zhang X, Zhang Y, Yang Y, et al. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 2012; 36:288-93.

136. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44:570-4.

137. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012; 33:100-3.

138. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43:1219-23.

139. Kimura Y, Noguchi T, Kawahara K, et al. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: Gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 2004; 17:1328-37.

140. Kim JH, Takahashi T, Chiba I, et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991; 83:938-43.

141. Victor T, Du Toit R, Jordaan AM, et al. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. Cancer Res 1990; 50:4911-4.

142. Han S, Kim HY, Park K, et al. Expression of p27Kip1 and cyclin D1 proteins is inversely correlated and is associated with poor clinical outcome in human gastric cancer. J Surg Oncol 1999; 71:147-54.

143. Kim DH, Lee HI, Nam ES, et al. Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2000; 36:245-51.

144. Takano Y, Kato Y, van Diest PJ, et al. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000; 156:585-94.

145. Myung N, Kim MR, Chung IP, et al. Loss of p16 and p27 is associated with progression of human gastric cancer. Cancer Lett 2000; 153:129-36.

146. Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000; 80:689-95.

147. Schneider BG, Gulley ML, Eagan P, et al. Loss of p16/ CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Hum Pathol 2000; 31:45-50.

148. Tsujie M, Yamamoto H, Tomita N, et al. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology 2000; 58:126-36.

149. Jiang L, Gonda TA, Gamble MV, et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 2009; 68:9900-8.

150. Stemmermann G, Heffelfinger SC, Noffsinger A, et al. The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors. Hum Pathol 1994; 25:968-81.

151. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.

152. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304:1164-6.

153. Park WS, Oh RR, Park JY, et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 2000; 119:691-8.

154. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109:113-24.

155. Yio X, Diamond M, Zhang JY, et al. Trefoil factor family-1 mutations enhance gastric cancer cell invasion through distinct signaling pathways. Gastroenterology 2006; 130:1696-706.

156. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 2008; 14:226-37.

157. Mironov NM, Aguelon MA, Potapova GI, et al. Alterations of (CA)n DNA repeats and tumor suppressor genes in human gastric cancer. Cancer Res 1994; 54:41-4.

158. Rhyu MG, Park WS, Meltzer SJ. Microsatellite instability occurs frequently in human gastric carcinoma. Oncogene 1994; 9:29-32.

159. Fang DC, Jass JR, Wang DX, et al. Infrequent loss of heterozygosity of APC/MCC and DCC genes in gastric cancer showing DNA microsatellite instability. J Clin Pathol 1999; 52:504-8.

160. Isogaki J, Shinmura K, Yin W, et al. Microsatellite instability and K-ras mutations in gastric adenomas, with reference to associated gastric cancers. Cancer Detect Prev 1999; 23:204-14.

161. Habano W, Sugai T, Nakamura SI, et al. Microsatellite instability and mutation of mitochondrial and nuclear DNA in gastric carcinoma. Gastroenterology 2000; 118:835-41.

162. Leung WK, Kim JJ, Kim JG, et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000; 156:537-43.

163. Yamamoto H, Perez-Piteira J, Yoshida T, et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999; 116:1348-57.

164. Paulson TG, Wright FA, Parker BA, et al. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 1996; 56:4021-6.

165. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999; 155:337-42.

166. Yoon KA, Ku JL, Yang HK, et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 1999; 44:177-80.

167. Xiangming C, Hokita S, Natsugoe S, et al. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 1999; 57:131-7.

168. Kawanishi K, Doki Y, Shiozaki H, et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am J Clin Pathol 2000; 113:266-74.

169. Shiozaki H, Oka H, Inoue M, et al. E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77:1605-13.

170. Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92:569-73.

171. Batlle E, Henderson JT, Beghtel H, et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002; 111:251-63.

172. Ouko L, Ziegler TR, Gu LH, et al. Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells. J Biol Chem 2004; 279:26707-15.

173. Yu J, Ebert MP, Miehlke S, et al. Alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives. Gut 2000; 46:639-44.

174. Zhu L, Gibson P, Currle DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457:603-7.

175. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449:1003-7.

176. Qiao XT, Ziel JW, McKimpson W, et al. Prospective identification of a multilineage progenitor in murine stomach epithelium. Gastroenterology 2007; 133:1989-98.

177. Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet 2008; 40:915-20.

178. Montgomery RK, Carlone DL, Richmond CA, et al. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. Proc Natl Acad Sci U S A 2011; 108:179-84.

179. Tian H, Biehs B, Warming S, et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011; 478:255-9.

180. Potten CS, Owen G, Booth D. Intestinal stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci 2002; 115:2381-8.

181. Quante M, Marrache F, Goldenring JR, Wang TC. TFF2 mRNA transcript expression marks a gland progenitor cell of the gastric oxyntic mucosa. Gastroenterology 2010; 139:2018-27.e2.

182. Means AL, Xu Y, Zhao A, et al. A CK19(CreERT) knockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organs. Genesis 2008; 46:318-23.

183. Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011; 474:318-26.

184. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8:90-100.

185. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-81.

186. Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 22:471-81.

187. Kokkola A, Sjoblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33:88-92.

188. Siurala M, Lehtola J, Ihamaki T. Atrophic gastritis and its sequelae. Results of 19-23 years’ follow-up examinations. Scand J Gastroenterol 1974; 9:441-6.

189. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 2007; 12:1-15.

190. Kato I, Tominaga S, Ito Y, et al. A prospective study of atrophic gastritis and stomach cancer risk. Jpn J Cancer Res 1992; 83:1137-42.

191. Tatsuta M, Iishi H, Nakaizumi A, et al. Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 1993; 53:70-4.

192. Cassaro M, Rugge M, Gutierrez O, et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95:1431-8.

193. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345:1525-8.

194. Asaka M, Sugiyama T, Nobuta A, et al. Atrophic gastritis and intestinal metaplasia in Japan: Results of a large multicenter study. Helicobacter 2001; 6:294-9.

195. Schafer LW, Larson DE, Melton LJ 3rd, et al. Risk of development of gastric carcinoma in patients with pernicious anemia: A population-based study in Rochester, Minnesota. Mayo Clin Proc 1985; 60:444-8.

196. Sobala GM, Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach. Gastroenterology 1989; 97:357-63.

197. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118:36-47.

198. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin–Active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 2006; 6:936-46.

199. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981; 13:931-9.

200. Leung WK, Sung JJ. Review article: Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002; 16:1209-16.

201. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991; 32:1110-3.

202. Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 1999; 79:639-46.

203. Halldorsdottir AM, Sigurdardottrir M, Jonasson JG, et al. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 2003; 48:431-41.

204. Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR. Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci 2002; 47:573-8.

205. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: The Padova international classification. Am J Surg Pathol 2000; 24:167-76.

206. de Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: Implications for the development of screening and surveillance strategies. Helicobacter 2007; 12(Suppl 2):22-31.

207. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993; 53:1317-21.

208. Rugge M, Farinati F, Di Mario F, et al. Gastric epithelial dysplasia: A prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 1991; 22:1002-8.

209. Di Gregorio C, Morandi P, Fante R, De Gaetani C. Gastric dysplasia. A follow-up study. Am J Gastroenterol 1993; 88:1714-9.

210. Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003; 52:1111-6.

211. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology 2008; 134:945-52.

212. Lansdown M, Quirke P, Dixon MF, et al. High grade dysplasia of the gastric mucosa: A marker for gastric carcinoma. Gut 1990; 31:977-83.

213. Kokkola A, Haapiainen R, Laxen F, et al. Risk of gastric carcinoma in patients with mucosal dysplasia associated with atrophic gastritis: A follow up study. J Clin Pathol 1996; 49:979-84.

214. Voutilainen M, Mantynen T, Kunnamo I, et al. Impact of clinical symptoms and referral volume on endoscopy for detecting peptic ulcer and gastric neoplasms. Scand J Gastroenterol 2003; 38:109-13.

215. Burt RW. Gastric fundic gland polyps. Gastroenterology 2003; 125:1462-9.

216. Borch K, Skarsgard J, Franzen L, et al. Benign gastric polyps: Morphological and functional origin. Dig Dis Sci 2003; 48:1292-7.

217. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24:1341-8.

218. Zea-Iriarte WL, Sekine I, Itsuno M, et al. Carcinoma in gastric hyperplastic polyps. A phenotypic study. Dig Dis Sci 1996; 41:377-86.

219. Dirschmid K, Platz-Baudin C, Stolte M. Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? Virchows Arch 2006; 448:80-4.

220. Kamiya T, Morishita T, Asakura H, et al. Long-term follow-up study on gastric adenoma and its relation to gastric protruded carcinoma. Cancer 1982; 50:2496-503.

221. Muehldorfer SM, Stolte M, Martus P, et al. Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: A prospective multicentre study. Gut 2002; 50:465-70.

222. Goddard AF, Badreldin R, Pritchard DM, et al. The management of gastric polyps. Gut 2010; 59:1270-6.

223. Caygill CP, Hill MJ, Kirkham JS, Northfield TC. Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1986; 1:929-31.

224. Viste A, Bjornestad E, Opheim P, et al. Risk of carcinoma following gastric operations for benign disease. A historical cohort study of 3470 patients. Lancet 1986; 2:502-5.

225. Lundegardh G, Adami HO, Helmick C, et al. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988; 319:195-200.

226. Dubrow R. Gastric cancer following peptic ulcer surgery. J Natl Cancer Inst 1993; 85:1268-70.

227. Domellof L, Eriksson S, Janunger KG. Carcinoma and possible precancerous changes of the gastric stump after billroth II resection. Gastroenterology 1977; 73:462-8.

228. Greenlee HB, Vivit R, Paez J, Dietz A. Bacterial flora of the jejunum following peptic ulcer surgery. Arch Surg 1971; 102:260-5.

229. Dewar P, Dixon MF, Johnston D. Bile reflux and degree of gastritis in patients with gastric ulcer: Before and after operation. J Surg Res 1984; 37:277-84.

230. MacDonald WC, Owen DA. Gastric carcinoma after surgical treatment of peptic ulcer: An analysis of morphologic features and a comparison with cancer in the nonoperated stomach. Cancer 2001; 91:1732-8.

231. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335:242-9.

232.     Molloy RM, Sonnenberg A. Relation between gastric cancer and previous peptic ulcer disease. Gut 1997; 40:247-52.

233.     Case records of the Massachusetts General Hospital. Case 2-1988. A 55-year-old man with innumerable gastric polyps and recent melena. N Engl J Med 1988; 318:100-9.

234.     Scharschmidt BF. The natural history of hypertrophic gastrophy (Menetrier’s disease). Report of a case with 16 year follow-up and review of 120 cases from the literature. Am J Med 1977; 63:644-52.

235.     Wood MG, Bates C, Brown RC, Losowsky MS. Intramucosal carcinoma of the gastric antrum complicating Menetrier’s disease. J Clin Pathol 1983; 36:1071-5.

236.     Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: Current evidence and practice. Lancet oncology 2008; 9:279-87.

237.     Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38:259-67.

238.     Watanabe H, Mai M, Shimoda T, et al. Meeting report of the 72nd Japanese Gastric Cancer Congress. Gastric Cancer 2000; 3:1-8.

239.     Naito Y, Uchiyama K, Kinoshita Y, et al. A questionnaire- based survey on screening for gastric and colorectal cancer by physicians in East Asian countries in 2010. Digestion 2012; 86:94-106.

240.     Kunisaki C, Ishino J, Nakajima S, et al. Outcomes of mass screening for gastric carcinoma. Ann Surg Oncol 2006; 13:221-8.

241.     Lee KJ, Inoue M, Otani T, et al. Gastric cancer screening and subsequent risk of gastric cancer: A large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006; 118:2315-21.

242.     Mizoue T, Yoshimura T, Tokui N, et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer 2003; 106:103-7.

243.     Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9:245-53.

244.     Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: A prospective endoscopic cohort study. Gut 2005; 54:764-8.

245.     Yanaoka K, Oka M, Yoshimura N, et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008; 123:917-26.

246.     Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4:709-16.

247.     Yeh JM, Hur C, Kuntz KM, et al. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116:2941-53.

248.     Moss SF. The carcinogenic effect of H. pylori on the gastric epithelial cell. J Physiol Pharmacol 1999; 50:847-56.

249.     Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003; 94:235-9.

250.     Zivny J, Wang TC, Yantiss R, et al. Role of therapy or monitoring in preventing progression to gastric cancer. J Clin Gastroenterol 2003; 36:S50-60; discussion S1-2.

251.     Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92:1881-8.

252.     Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000; 119:7-14.

253.     Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004; 291:187-94.

254.     Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: A randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004; 13:4-10.

255.     Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53:1244-9.

256.     Dixon MF. Prospects for intervention in gastric carcinogenesis: Reversibility of gastric atrophy and intestinal metaplasia. Gut 2001; 49:2-4.

257.     Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151:121-8.

258.     Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet 2008; 372:392-7.

259.     Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996; 348:150-4.

260.     Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: A Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002; 16:559-68.

261.     Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002; 29:111-9.

262.     Saukkonen K, Rintahaka J, Sivula A, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003; 111:915-25.

263.     Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57:1276-80.

264.     Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94:451-5.

265.     Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274:G1061-7.

266.     Yamamoto H, Itoh F, Fukushima H, et al. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int J Cancer 1999; 84:400-3.

267.     van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002; 196:171-9.

268.     Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157:729-35.

269.     Akre K, Ekstrom AM, Signorello LB, et al. Aspirin and risk for gastric cancer: A population-based case-control study in Sweden. Br J Cancer 2001; 84:965-8.

270.     Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of  esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2008; 17:126-34.

271.     Wang WH, Huang JQ, Zheng GF, et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: A systematic review and meta-analysis. J Natl Cancer Inst 2003; 95:1784-91.

272. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:444-50.

273. Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: Results of a randomized controlled trial. Clin Cancer Res 2006; 12:4766-72.

274. Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61:812-8.

275. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41.

276. Osmak M. Statins and cancer: Current and future prospects. Cancer Lett 2012; 324:1-12.

277. Chiu HF, Ho SC, Chang CC, et al. Statins are associated with a reduced risk of gastric cancer: A population-based case-control study. Am J Gastroenterol 2011; 106:2098-103.

278. Lee J, Lee SH, Hur KY, et al. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 2012; 12:596.

279. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22:2388-94.

280. Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121:2381-6.

281. Jenab M, Riboli E, Ferrari P, et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer 2006; 95:406-15.

282. Jenab M, Riboli E, Ferrari P, et al. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Carcinogenesis 2006; 27:2250-7.

283. Persson C, Sasazuki S, Inoue M, et al. Plasma levels of carotenoids, retinol and tocopherol and the risk of gastric cancer in Japan: A nested case-control study. Carcinogenesis 2008; 29:1042-8.

284. Ja Kim H, Lee SS, Choi BY, Kim MK. Nitrate intake relative to antioxidant vitamin intake affects gastric cancer risk: A case-control study in Korea. Nutr Cancer 2007; 59:185-91.

285. Larsson SC, Bergkvist L, Naslund I, et al. Vitamin A, retinol, and carotenoids and the risk of gastric cancer: A prospective cohort study. Am J Clin Nutr 2007; 85:497-503.

286. Plummer M, Vivas J, Lopez G, et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: A randomized trial in a high-risk population. J Natl Cancer Inst 2007; 99:137-46.

287. You WC, Brown LM, Zhang L, et al. Randomized double- blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98:974-83.

288. Qiao YL, Dawsey SM, Kamangar F, et al. Total and cancer mortality after supplementation with vitamins and minerals: Follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 2009; 101:507-18.

289. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-5.

290. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001; 7:4220-9.

291. Ahmad N, Feyes DK, Nieminen AL, et al. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89:1881-6.

292. Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003; 9:3486-91.

293. Saffari Y, Sadrzadeh SM. Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sci 2004; 74:1513-8.

294. D’Alessandro T, Prasain J, Benton MR, et al. Polyphenols, inflammatory response, and cancer prevention: Chlorination of isoflavones by human neutrophils. J Nutr 2003; 133:3773S-7S.

295. Tsubono Y, Nishino Y, Komatsu S, et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001; 344:632-6.

296. Sasazuki S, Tamakoshi A, Matsuo K, et al. Green tea consumption and gastric cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012; 42:335-46.

297. Sasazuki S, Inoue M, Hanaoka T, et al. Green tea consumption and subsequent risk of gastric cancer by subsite: The JPHC Study. Cancer Causes Control 2004; 15:483-91.

298. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218:583-92.

299. Tucker HJ, Snape WJ Jr, Cohen S. Achalasia secondary to carcinoma: Manometric and clinical features. Ann Intern Med 1978; 89:315-8.

300. Wakashin M, Wakashin Y, Iesato K, et al. Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients. Gastroenterology 1980; 78:749-56.

301. Gragasin-Saviano L, Isaacson E, Stuck RM. Pedal gangrene secondary to disseminated intravascular coagulation with gastric carcinoma. J Am Podiatr Med Assoc 2002; 92:149-52.

302. Croft PB, Wilkinson M. The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain 1965; 88:427-34.

303. Yeh JS, Munn SE, Plunkett TA, et al. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: A case report and literature review. J Am Acad Dermatol 2000; 42:357-62.

304. Dupont JB Jr, Lee JR, Burton GR, Cohn I Jr. Adenocarcinoma of the stomach: Review of 1,497 cases. Cancer 1978; 41:941-7.

305. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.

306. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106:1624-33.

307. Hornung M, Vogel P, Schubert T, et al. A case of virilization induced by a Krukenberg tumor from gastric cancer. World J Surg Oncol 2008; 6:19.

308. Massarotti M, Ciocia G, Ceriani R, et al. Metastatic gastric cancer presenting with shoulder-hand syndrome: A case report. J Med Case Rep 2008; 2:240.

309. Yunker JJ, Vicinanzo MG, Braswell RA, et al. Unusual presentation of gastric adenocarcinoma metastatic to the orbit. Ophthal Plast Reconstr Surg 2006; 22:490-1.

310. Saornil MA, Blanco G, Sarasa JL, et al. Isolated metastasis of gastric adenocarcinoma to the retina: First presentation of systemic disease. Acta Ophthalmol Scand 2004; 82:86-8.

311. Farley DR, Donohue JH. Early gastric cancer. Surg Clin North Am 1992; 72:401-21.

312. Talley NJ. American Gastroenterological Association medical position statement: Evaluation of dyspepsia. Gastroenterology 2005; 129:1753-5.

313. Tanaka K, Toyoda H, Kadowaki S, et al. Surface pattern classification by enhanced-magnification endoscopy for identifying early gastric cancers. Gastrointest Endosc 2008; 67:430-7.

314. Kato M, Kaise M, Yonezawa J, et al. Autofluorescence endoscopy versus conventional white light endoscopy for the detection of superficial gastric neoplasia: A prospective comparative study. Endoscopy 2007; 39:937-41.

315. Kitabatake S, Niwa Y, Miyahara R, et al. Confocal endomicroscopy for the diagnosis of gastric cancer in vivo. Endoscopy 2006; 38:1110-4.

316. Archer AG, Grant DC. Recent developments in diagnostic radiology of primary and recurrent gastric cancer. Cancer Treat Res 1991; 55:107-31.

317. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon. Gastrointest Endosc 2003; 58:S3-28.

318. Shin KS, Kim SH, Han JK, et al. Three-dimensional MDCT gastrography compared with axial CT for the detection of early gastric cancer. J Comput Assist Tomogr 2007; 31:741-9.

319. Kitahara F, Kobayashi K, Sato T, et al. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44:693-7.

320. Westerveld BD, Pals G, Lamers CB, et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 1987; 59:952-8.

321. Ohata H, Oka M, Yanaoka K, et al. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. Cancer Sci 2005; 96:713-20.

322. Mukoubayashi C, Yanaoka K, Ohata H, et al. Serum pepsinogen and gastric cancer screening. Intern Med 2007; 46:261-6.

323. Fernandez-Fernandez L, Tejero E, Tieso A, et al. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer. Int Surg 1996; 81:400-2.

324. Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study. Gastric Cancer 2003; 6:142-5.

325. Li X, Yue ZC, Zhang YY, et al. Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal 2008; 22:164-71.

326. Goral V, Yesilbagdan H, Kaplan A, Sit D. Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology 2007; 54:1272-5.

327. Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: A gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007; 19:265-76.

328. Tanaka K, Miki C, Wakuda R, et al. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 2004; 39:754-60.

329. Fujiwara M, Kodera Y, Misawa K, et al. Long-term outcomes of early-stage gastric carcinoma patients treated with laparoscopy-assisted surgery. J Am Coll Surg 2008; 206:138-43.

330. Kitano S, Shiraishi N, Uyama I, et al. A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007; 245:68-72.

331. Borie F, Plaisant N, Millat B, et al. Appropriate gastric resection with lymph node dissection for early gastric cancer. Ann Surg Oncol 2004; 11:512-7.

332. Yamashita K, Sakuramoto S, Kikuchi S, et al. Validation of staging systems for gastric cancer. Gastric Cancer 2008; 11:111-8.

333. Sobin LH, Wittekind C. TNM Classification of malignant tumors (UICC). New York: John Wiley; 1997.

334. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

335. Tan IB, Ivanova T, Lim KH, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011; 141:476-85, 85 e1-11.

336. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: A meta-analysis. Gastrointest Endosc 2011; 73:1122-34.

337. Okada K, Fujisaki J, Kasuga A, et al. Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. Surg Endosc 2011; 25:841-8.

338. Habermann CR, Weiss F, Riecken R, et al. Preoperative staging of gastric adenocarcinoma: Comparison of helical CT and endoscopic US. Radiology 2004; 230:465-71.

339. Polkowski M, Palucki J, Wronska E, et al. Endosonography versus helical computed tomography for locoregional staging of gastric cancer. Endoscopy 2004; 36:617-23.

340. Kwee RM, Kwee TC. Imaging in local staging of gastri cancer: A systematic review. J Clin Oncol 2007; 25:2107-16.

341. Makino T, Fujiwara Y, Takiguchi S, et al. Preoperative T staging of gastric cancer by multi-detector row computed tomography. Surgery 2011; 149:672-9.

342. Yang DM, Kim HC, Jin W, et al. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: Histological correlation. J Comput Assist Tomogr 2007; 31:98-103.

343. Bhandari S, Shim CS, Kim JH, et al. Usefulness of three- dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: A comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc 2004; 59:619-26.

344. Lim JS, Yun MJ, Kim MJ, et al. CT and PET in stomach cancer: Preoperative staging and monitoring of response to therapy. Radiographics 2006; 26:143-56.

345. Smyth E, Schoder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D- glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012; 118:5481-8.

346. Wong J, Coit D. Detection of gastric cancer peritoneal metastases by peritoneal lavage: Current limitations and future perspectives. Surgery 2012; 152:1-4.

347. Gastric Cancer. National Comprehensive Cancer Network, 2013. (Accessed March 11, 2013, at http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.)

348. Karanicolas PJ, Elkin EB, Jacks LM, et al. Staging laparoscopy in the management of gastric cancer: A population-based analysis. J Am Coll Surg 2011; 213:644-51, 51 e1.

349. Park SR, Lee JS, Kim CG, et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer 2008; 112:2368-76.

350. Patel PR, Mansfield PF, Crane CH, et al. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer 2007; 110:989-95.

351. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88:921-32.

352. Zu H, Wang F, Ma Y, Xue Y. Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer. PLoS One 2013; 8:e54502.

353. Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer 2007; 10:29-34.

354. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989; 209:162-6.

355. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230:170-8.

356. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79:1522-30.

357. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93:559-63.

358. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22:2069-77.

359. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11:439-49.

360. Van Cutsem E, Van de Velde C, Roth A, et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008; 44:182-94.

361. Yamao T, Shirao K, Ono H, et al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer 1996; 77:602-6.

362. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005; 23:4490-8.

363. Lee TH, Cho JY, Chang YW, et al. Appropriate indications for endoscopic submucosal dissection of early gastric cancer according to tumor size and histologic type. Gastrointest Endosc 2010; 71:920-6.

364. Kakushima N, Fujishiro M. Endoscopic submucosal dissection for gastrointestinal neoplasms. World J Gastroenterol 2008; 14:2962-7.

365. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: Estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3:219-25.

366. Isomoto H, Shikuwa S, Yamaguchi N, et al. Endoscopic submucosal dissection for early gastric cancer: A large-scale feasibility study. Gut 2009; 58:331-6.

367. Imagawa A, Okada H, Kawahara Y, et al. Endoscopic submucosal dissection for early gastric cancer: Results and degrees of technical difficulty as well as success. Endoscopy 2006; 38:987-90.

368. Onozato Y, Ishihara H, Iizuka H, et al. Endoscopic submucosal dissection for early gastric cancers and large flat adenomas. Endoscopy 2006; 38:980-6.

369. Probst A, Pommer B, Golger D, et al. Endoscopic submucosal dissection in gastric neoplasia—Experience from a European center. Endoscopy 2010; 42:1037-44.

370. Farhat S, Chaussade S, Ponchon T, et al. Endoscopic submucosal dissection in a European setting. A multi- institutional report of a technique in development. Endoscopy 2011; 43:664-70.

371. Abe N, Takeuchi H, Ohki A, et al. Long-term outcomes of combination of endoscopic submucosal dissection and laparoscopic lymph node dissection without gastrectomy for early gastric cancer patients who have a potential riskof lymph node metastasis. Gastrointest Endosc 2011; 74:792-7.

372. Nicholson DA, Shorvon PJ. Review article: Endoscopic ultrasound of the stomach. Br J Radiol 1993; 66:487-92.

373. De Vita F, Giuliani F, Galizia G, et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007; 18(Suppl 6):vi120-3.

374. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059-64.

375. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168:597-608.

376. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008; 100:388-98.

377. Bouche O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16:1488-97.

378. Lindsay S, Thiselton DL, Bateman JB, et al. Localisation of the gene for Norrie disease to between DXS7 and DXS426 on Xp. Hum Genet 1992; 88:349-50.

379. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20.

380. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-30.

381. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24:3953-8.

382. Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomized trial. World J Surg 2001; 25:985-90.

383. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study. Hepatogastroenterology 2001; 48:1776-82.

384. Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12:970-4.

385. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998; 16:2733-8.

386. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007; 14:2702-13.

387. Cascinu S, Scartozzi M, Labianca R, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 2004; 90:1521-5.

388. Schuhmacher CP, Fink U, Becker K, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 91:918-27.

389. Cervantes A, Rosello S, Roda D, Rodriguez-Braun E. The treatment of advanced gastric cancer: Current strategies and future perspectives. Ann Oncol 2008; 19(Suppl 5):v103-7.

390. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; CD004064.

391. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97.

392. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119-27.

393. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29:3968-76.

394. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial. Lancet Oncol 2012; 13:1225-33.

395. Andre T, Larsen AK, de Gramont AAdjuvant bevacizumab and cetuximab for stage III colon cancer: Why such failure in an adjuvant situation?. Bull Cancer 2012; 99:607-8.

396. Chibaudel B, Tournigand C, Andre T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012; 4:75-89.

397. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996-2004.

398. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal canceradenocarcinoma: The V-325 Study Group. J Clin Oncol 2007; 25:3205-9.

399. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.

400. Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013 [in press].

401. Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011; 22(Suppl 5):v1-9.

402. Park JS, Lim JY, Park SK, et al. Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat 2011; 43:236-43.

403. Sankary H, Foster P, Novich K, et al. Quantitative analysis of portal tract infiltrate allows for accurate determination of hepatic allograft rejection. Am J Surg 1991; 161:131-4; discussion 4-5.

404. Jeurnink SM, van Eijck CH, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: A systematic review. BMC Gastroenterol 2007; 7:18.

405. Campoli PM, Ejima FH, Cardoso DM, et al. Metastatic cancer to the stomach. Gastric Cancer 2006; 9:19-25.

406. Stein L, Urban MI, O’Connell D, et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: Results from a case-control study, 1995-2004. Int J Cancer 2008; 122:2260-5.

407. Hong HS, Ha HK, Won HJ, et al. Gastric schwannomas: Radiological features with endoscopic and pathological correlation. Clin Radiol 2008; 63:536-42.

408. Otsuji E, Yamaguchi T, Taniguchi H, et al. Malignant endocrine carcinoma of the stomach. Hepatogastroenterology 2000; 47:601-4.

409. Yang GY, Liao J, Cassai ND, et al. Parietal cell carcinoma of gastric cardia: Immunophenotype and ultrastructure. Ultrastruct Pathol 2003; 27:87-94.